Table 2.
Ongoing and planned clinical trials with 211At. (NTC number) is the ClinicalTrials.gov identifier.
| Institution, reference | Clinical situation |
Planned size
(nb Pts.) |
Study objective(s) | TAT-agent/ Carrier | Target | Primary outcome |
|---|---|---|---|---|---|---|
| Fred Hutchinson Cancer Center, Seattle, USA (NCT04466475) | Multiple Myeloma | 24 | Feasibility and safety | 211At-OKT10-B10 | CD38 | MTD |
| Fred Hutchinson Cancer Center, Seattle, USA (NCT04579523) | Multiple Myeloma | 30 | Dose escalation | 211At-OKT10-B10 | CD38 | MTD |
| Fred Hutchinson Cancer Center, Seattle, USA (NCT04083183) | HCT for non-malignant disease | 40 | Dose escalation | 211At- BC8-B10 | CD45 | Graft rejection |
| Fred Hutchinson Cancer Center, Seattle, USA (NCT03670966) | High-risk acute leukemia or MDS | 30 | Dose-escalation | 211At- BC8-B10 | CD45 | Toxicity |
| Fred Hutchinson Cancer Center, Seattle, USA (NCT03128034) | High-risk AML, ALL, MDS or Mixed-phenotype acute leukemia | 50 | Dose-escalation | 211At- BC8-B10 | CD45 | Toxicity, MTD |
| Osaka University Hospital, Suita, Japan (NCT05275946) | Thyroid cancer | 11 | To establish recommended dose for Phase II trial | [211At] NaAt | NIS | Treatment-related adverse events |
| Fukushima Medical University, Japan | Malignant pheochromocytoma | Up to 18 | Dose escalation | 211At-MABG | Norepinephrine transporter | Toxicity, MTD |
HCT, Hematopoietic cell transplantation.